These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

59 related items for PubMed ID: 2912742

  • 1. Natural killer cell-mediated inhibition of growth of myeloid and lymphoid clonogenic leukemias.
    Savary CA, Lotzová E.
    Exp Hematol; 1989 Feb; 17(2):183-7. PubMed ID: 2912742
    [Abstract] [Full Text] [Related]

  • 2. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, O'Reilly RJ.
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [Abstract] [Full Text] [Related]

  • 3. Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia.
    Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J.
    Exp Hematol; 1996 Feb; 24(3):406-15. PubMed ID: 8599969
    [Abstract] [Full Text] [Related]

  • 4. IFN-gamma treatment of K562 cells inhibits natural killer cell triggering and decreases the susceptibility to lysis by cytoplasmic granules from large granular lymphocytes.
    Grönberg A, Ferm MT, Ng J, Reynolds CW, Ortaldo JR.
    J Immunol; 1988 Jun 15; 140(12):4397-402. PubMed ID: 3131433
    [Abstract] [Full Text] [Related]

  • 5. Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia.
    Meseri-Delwail A, Delwail V, Brizard A, Goube de Laforest P, Guilhot F, Lecron JC.
    Biotechnol Ther; 1994 Jun 15; 5(1-2):47-57. PubMed ID: 7703832
    [Abstract] [Full Text] [Related]

  • 6. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.
    Peters PM, Ortaldo JR, Shalaby MR, Svedersky LP, Nedwin GE, Bringman TS, Hass PE, Aggarwal BB, Herberman RB, Goeddel DV.
    J Immunol; 1986 Oct 15; 137(8):2592-8. PubMed ID: 3760569
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mechanism of defective NK cell activity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibody-dependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity.
    Katz JD, Mitsuyasu R, Gottlieb MS, Lebow LT, Bonavida B.
    J Immunol; 1987 Jul 01; 139(1):55-60. PubMed ID: 3584988
    [Abstract] [Full Text] [Related]

  • 9. Analysis of rat natural killer cytotoxic factor (NKCF) produced by rat NK cell lines and the production of a murine monoclonal antibody that neutralizes NKCF.
    Ortaldo JR, Winkler-Pickett R, Morgan AC, Woodhouse C, Kantor R, Reynolds CW.
    J Immunol; 1987 Nov 01; 139(9):3159-65. PubMed ID: 3668253
    [Abstract] [Full Text] [Related]

  • 10. Lysis of fresh leukemic blasts by interferon-activated human natural killer cells.
    Pattengale PK, Sundstrom C, Yu AL, Levine A.
    Nat Immun Cell Growth Regul; 1987 Nov 01; 3(4):165-80. PubMed ID: 6597341
    [Abstract] [Full Text] [Related]

  • 11. Studies on the mechanism of natural killer cell-mediated cytotoxicity. IV. Interferon-induced inhibition of NK target cell susceptibility to lysis is due to a defect in their ability to stimulate release of natural killer cytotoxic factors (NKCF).
    Wright SC, Bonavida B.
    J Immunol; 1983 Jun 01; 130(6):2965-8. PubMed ID: 6189909
    [Abstract] [Full Text] [Related]

  • 12. BCR/ABL-negative clonogenic hematopoietic cells do not accumulate in the plastic-adherent fraction of peripheral blood mononuclear cells from patients with chronic myeloid leukemia in stable chronic phase.
    Schultheis B, Pasternak G, Hehlmann R.
    Folia Biol (Praha); 2000 Jun 01; 46(6):256-63. PubMed ID: 11140859
    [Abstract] [Full Text] [Related]

  • 13. An Hsp70 peptide initiates NK cell killing of leukemic blasts after stem cell transplantation.
    Gross C, Holler E, Stangl S, Dickinson A, Pockley AG, Asea AA, Mallappa N, Multhoff G.
    Leuk Res; 2008 Apr 01; 32(4):527-34. PubMed ID: 17543383
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase.
    Beran M, Pisa P, O'Brien S, Kurzrock R, Siciliano M, Cork A, Andersson BS, Kohli V, Kantarjian H.
    Cancer Res; 1993 Aug 01; 53(15):3603-10. PubMed ID: 8339266
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mechanism of cell-mediated cytotoxicity at the single cell level. VI. Direct assessment of the cytotoxic potential of human peripheral blood non-lytic effector-target cell conjugates.
    Bonavida B, Lebow LT, Bradley TP.
    J Immunol; 1984 Feb 01; 132(2):594-8. PubMed ID: 6606675
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.
    Cebo C, Voutsadakis IA, Da Rocha S, Bourhis JH, Jalil A, Azzarone B, Turhan AG, Chelbi-Alix M, Chouaib S, Caignard A.
    Cancer Res; 2005 Apr 01; 65(7):2914-20. PubMed ID: 15805294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.